ANGO
Fiscal year ends May Quarters are offset from the calendar — Q1 is Jun–Aug

AngioDynamics, Inc. is a medical technology company that designs, manufactures, and sells products and technologies for the treatment of patients with cardiovascular disease and cancer. The company operates in two segments: Med Tech and Med Device. Its Med Tech portfolio includes the Auryon Atherectomy System for peripheral arterial disease, the NanoKnife IRE Ablation System for soft tissue and prostate ablation, and thrombus management solutions such as the AngioVac venous drainage system, AlphaVac mechanical thrombectomy system, and Uni-Fuse thrombolytic catheters. The Med Device segment offers a comprehensive line of interventional devices, including angiographic catheters, guidewires, drainage catheters, and micropuncture kits. Founded in 1988, the company has grown through acquisitions of RITA Medical Systems, Oncobionic, Diomed, Vortex Medical, Microsulis Medical, and Clinical Devices. AngioDynamics serves healthcare professionals globally, with operations in North America, Europe, Asia, and South America, and its products are cleared for sale in the United States by the FDA.

Summarised from the company's own disclosures, fiscal year ended Jul 2026

Industry Medical Devices Homepage angiodynamics.com
Sector Healthcare IR page angiodynamics.com
Tags
cardiovascular disease, cancer treatment, peripheral arterial disease, ablation, thrombectomy, angiography, venous drainage, minimally invasive procedures, medical technology, interventional radiology, Auryon, NanoKnife, AngioVac, AlphaVac, Uni-Fuse, Uni-Fuse+, Soft-Vu, RITA Medical Systems, Oncobionic, Diomed, Vortex Medical, Microsulis Medical, Clinical Devices, Eximo Medical, Camaro Support Catheter, C3 Wave, BioSentry, RadiaDyne
Press page —

Metrics

Valuation  
Market cap $ 520.548M
Market cap (USD) $ 520.548M
P/E -15.53
PEG —
P/BV 3.17
P/S 1.60
P/OCF 141.72
P/FCF 360.49
Dividend yield —
Turnover / mcap —
Returns  
ROE -20.8%
ROI -30.0%
ROIC -24.5%
Profit margin -11.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 45
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Revenue 320.174M 292.498M 303.914M 338.752M 316.219M 291.01M 264.157M 270.634M 344.285M 349.643M 353.89M 356.974M 354.455M 342.026M 221.787M 215.75M 195.054M 166.5M 112.227M 78.451M 60.289M 49.055M 38.434M
Net profit -36.742M -33.993M -184.349M -52.442M -26.547M -31.548M -166.787M 61.34M 16.335M 5.008M -43.59M -3.268M 3.088M -612K -5.094M 8.117M 9.932M 10.889M -9.127M 6.866M 4.548M 3.143M 1.186M
Free cash flow 508K -14.592M -30.676M -3.734M -11.491M 18.906M -21.789M 34.322M 38.896M 52.744M 42.89M 14.302M 13.509M 14.763M 9.005M 30.913M 15.581M 19.196M 2.978M 36K 2.963M 865K -3.382M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Share price 11.37 9.39 6.7 10.34 22.44 23.93 10.43 22.86 17.25 16 12.31 17.79 13.9 10.38 12.42 14.29 12 15.13 25 27.56 — — —
Price performance 12m 0.21 0.4 -0.35 -0.54 -0.06 1.29 -0.54 0.33 0.08 0.3 -0.31 0.28 0.34 -0.16 -0.13 -0.08 -0.21 -0.39 -0.09 — — — —

Filed figures

Figure May 2017 May 2018 May 2019 May 2020 May 2021 May 2022 May 2023 May 2024 May 2025 May 2026
Balance sheet detail
Trade receivables (USD) 44.5M 39.4M 43.6M 31.3M 35.4M 52.3M 52.8M 43.6M 42.9M 48.3M
↳ YoY growth -15.8% -11.5% +10.6% -28.3% +13.2% +47.7% +1.0% -17.4% -1.7% +12.7%
↳ 5y CAGR -1.7% -3.8% -6.9% -11.8% -7.7% +3.3% +6.0% +0.0% +6.5% +6.4%
Borrowings, current (USD) 5M 5M 7.5M 0.00 — — — — — —
Borrowings, non-current (USD) 91.3M 86.6M 124M — — — — — — —
Lease liabilities (USD) — — — 10.4M 9.73M 7.26M 5.24M 5.91M 10.1M 11M
Cash and deposits (USD) 47.5M 74.1M 228M 54.4M 48.2M 28.8M 44.6M 76.1M 55.9M 53.9M
Intangible assets (USD) 146M 130M 145M 197M 169M 152M 111M 77.4M 69.1M 67.2M
Right-of-use assets (USD) — — — 10.1M 9.38M 6.97M 5.11M 5.8M 3.85M 5.05M
Net debt (borrowings + leases - cash) (USD) 48.8M 17.5M -95.7M -44M — — — — — —
Cash flow detail
Operating cash flow (USD) 55.7M 41.3M 37.4M -14.6M 24.1M -7.19M 78,000 -28.2M -10.1M 3.09M
Purchases of property, plant and equipment (USD) -3M -2.39M -3.12M -7.24M -5.19M -4.3M -3.81M -2.52M -4.46M -2.58M
Change in receivables (cash effect) (USD) 8.48M 5.04M -3.18M 11.9M -4.16M -17.2M -1.3M 7.89M 23,000 -5.75M
Change in inventories (cash effect) (USD) 687,000 5.74M -1.43M -18.8M 11.5M -2.8M -8.2M -9.41M -1.35M 10M
Change in payables (cash effect) (USD) 19.2M -7.09M 5.21M -15.5M 4.88M 3.91M 2.14M 27.5M -15.9M -5.83M
Share buybacks (cash effect) (USD) -13.6M 0.00 0.00 — — — 0.00 0.00 -1.67M 0.00
Interest paid (cash effect) (USD) -2.97M -3.19M -5.12M -413,000 -731,000 -562,000 -2.58M 0.00 -185,000 -426,000
Income taxes paid (cash effect) (USD) -102,000 -36,000 -426,000 -682,000 -313,000 -329,000 -342,000 -455,000 -800,000 -405,000
Share-based compensation (USD) 6.18M 7.91M 9.25M 7.59M 8.63M 10.7M 11.2M 10.5M 9.77M 14M
Operating cash flow before change in receivables (USD) 47.3M 36.2M 40.6M -26.5M 28.3M 9.96M 1.38M -36.1M -10.2M 8.84M
Free cash flow (OCF - PPE - intangibles) (USD) 52.7M 38.9M 34.3M -21.8M 18.9M -11.5M -3.73M -30.7M -14.6M 508,000
Income detail
Research and development expense (USD) 25.3M 25.5M 28.3M 29.7M 36.4M 30.7M 29.9M 31.5M 26.2M 29.4M
↳ 5y CAGR +4.3% -0.7% +0.5% +2.0% +7.8% +4.0% +3.3% +2.2% -2.4% -4.1%
Total comprehensive income (USD) — 16.7M 60.9M -167M -27.1M -28.3M -58.5M -184M -31.7M -27M
Comprehensive income to owners (USD) — 16.7M 60.9M -167M -27.1M -28.3M -58.5M -184M -31.7M -27M
Provision for credit losses (USD) -313,000 179,000 -202,000 429,000 207,000 118,000 695,000 1.33M 699,000 313,000
Credit cost ratio (credit losses / average receivables) (%) 0.6% 0.4% 0.5% 1.1% 0.6% 0.3% 1.3% 2.8% 1.6% 0.7%
Reported Aug 4, 2017 Aug 10, 2020 Aug 10, 2020 Aug 10, 2020 Jul 27, 2021 Jul 22, 2022 Jul 18, 2025 Jul 18, 2025 Jul 18, 2025 Jul 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) As described below, the shareholders of AngioDynamics, Inc. (“AngioDynamics”) voted on November 17, 2026 to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) to increase the number of shares available for issuance. The material terms of the 2020 Plan are described in Proposal 4 included in AngioDynamics’ definitive proxy statement filed with the Securities and Exchange Commission on October 8, 2026, which description does not purport to be complete and is qualified in its entirety by reference to the full text of the 2020 Plan, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Submission of Matters to a Vote of Security Holders.

(a) The Annual Meeting of Shareholders of AngioDynamics was held on November 17, 2026.

(b) Shareholders of AngioDynamics voted on the matters set forth below.

1.

November 6, 2026

PDF Version

LATHAM, N.Y.--(BUSINESS WIRE)--Nov. 6, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026.

On November 2, 2026 (the “Grant Date”), as an inducement material to Mr. Honroth entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to approval by the independent Compensation Committee of the Board of Directors of the Company (the “Committee”), the Company granted to Mr. Honroth (i) time-based restricted stock units with respect to 62,928 shares of Common Stock of the Company (the “First Sign-On Award”), (ii) performance-based restricted stock units with respect to 62,928 shares of Common Stock of the Company at the target level of performance (the “Second Sign-On Award”) and (iii) time-based restricted stock units with respect to 38,265 shares of Common Stock of the Company (the “Third Sign-On Award”).

The First Sign-On Award will vest in equal annual installments over four years, subject to Mr. Honroth’s continued service through each applicable vesting date.

The Second Sign-On Award will vest, if at all, based on a combination of the Company’s revenue, adjusted EBITDA, and relative total shareholder return over a three-year performance period, subject to Mr. Honroth’s continued service through the date of the Committee’s certification as to whether or not the threshold performance metrics have been met. The number of shares that may be earned under the PSUs ranges from 0% of target to 240% of target.

The Third Sign-On Award will vest in two equal installments on November 2, 2027 and November 2, 2028, subject to Mr. Honroth’s continued service through each applicable vesting date.

**About AngioDynamics, Inc.**AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106038551/en/

Investor Contact: Stephen Trowbridge Executive Vice President & CFO 518-795-1408 [email protected]

Media Contact: Saleem Cheeks Vice President, Communications 518-795-1174 [email protected]

Source: AngioDynamics, Inc.

October 29, 2026

PDF Version

LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 29, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management is scheduled to participate in the following upcoming investor conferences:

UBS Global Healthcare ConferenceFireside Chat: Monday, November 9, 2026, from 8:00-8:35 AM ET

Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services ForumPresentation: Wednesday, November 11, 2026, from 1:00-1:25 PM ET A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029190648/en/

Investors: Stephen Trowbridge Executive Vice President & CFO 518-795-1408 [email protected]

Media: Saleem Cheeks Vice President, Communications 518-795-1174 [email protected]

Source: AngioDynamics, Inc.

Prompts

AngioDynamics, Inc. (ticker ANGO), listed in United States.

ETFs Holding AngioDynamics, Inc.

ETF Weight in ETF Shares Market value As of
RUSC 0.10% 6,246 $ 81.26K Jun 30, 2026
VFMF 0.08% 50,263 $ 810.742K Aug 31, 2026
AVSC 0.04% 95,638 $ 1.127M Nov 16, 2026
VFQY 0.03% 9,180 $ 148.073K Aug 31, 2026
RESM 0.02% 62 $ 806.62 Jun 30, 2026
FESM 0.02% 97,802 $ 1.272M Jun 30, 2026
DFAS 0.01% 312,795 $ 3.749M Nov 12, 2026
MSSM 0.01% 4,434 $ 71.52K Aug 31, 2026
DFAC 0.00% 202,349 $ 2.425M Nov 12, 2026
DCOR 0.00% 59,619 $ 714.534K Nov 12, 2026
DFSU 0.00% 3,043 $ 36.47K Nov 12, 2026
DFAU 0.00% 10,769 $ 129.066K Nov 12, 2026
DFUS 0.00% 10,723 $ 128.515K Nov 12, 2026
DXUV 0.00% 3,066 $ 36.746K Nov 12, 2026
AVUS 0.00% 3,255 $ 38.344K Nov 16, 2026